newsfilter
← Latest News
PR Newswire·

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

BRUSSELS and ATLANTA, Jan. 21, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the efficacy and safety of bimekizumab in the treatment of adults w